‘Pradaxa 75mg’ approval voluntarily withdrawn due to insufficient usage
Boehringer Ingelheim was confirmed to voluntarily withdraw Korean approval of the low volume of its novel oral anticoagulant, ‘Pradaxa(generic name: dabigatran).’ It has been a year since it acquired the approval on August last year.
Thus, Pradaxa 75mg returned the ‘Venous Thromboembolism Preven...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
